Travaxal, eye drops 0.04 mg/ml 2.5ml

Pharmacotherapeutic group: Antiglaucoma agent – synthetic prostaglandin F2-alpha analogue.

ATX code: S01EE04

Pharmacological properties

Indications

Active ingredient

Composition

How to take, the dosage

Topically.

1 drop into the conjunctival sac of the eye (eye) once a day, in the evening. To reduce the risk of systemic side effects, it is recommended that after instillation of the drug the nasolacrimal duct be compressed by pressing on its projection area at the inner corner of the eye.

If a dose of the drug is missed, treatment should be continued with the next dose. The daily dose of the drug should not exceed 1 drop in the conjunctival sac of the eye once a day.

The drug may be used in combination with other local ophthalmic drugs to reduce intraocular pressure. In this case, the interval between their administration should be at least 5 minutes.

If the drug is prescribed as a substitute for another ophthalmic glaucoma drug, the latter should be discontinued and Travaxal started the next day.

Principle procedure:

Special Instructions

The drug may cause a gradual change in eye color by increasing the number of melanosomes (pigment granules) in the melanocytes. This effect is mainly seen in patients with mixed iris coloration such as blue-brown, gray-brown, green-brown, or yellow-brown. This effect has also been noted in patients with brown iris coloration. The brown pigmentation usually spreads concentrically around the pupil to the periphery of the iris of the eye, with all or part of the iris becoming more intense brown. The long-term effects on melanocytes and the consequences are currently unknown. Changes in iris color occur slowly and may go undetected for months or years. Patients should be informed of the possibility of irreversible changes in eye color before starting treatment. If only one eye is treated, persistent heterochromia may develop. No further increase in brown iris pigmentation was noted after the end of therapy with travoprost.

Darkening of the eyelid skin and/or periorbital area has been reported in 0.4% of patients due to the use of travoprost.

Travoprost can gradually change the lash structure of the eye on which it is used; during clinical trials, such changes were observed in approximately half of patients and included increases in lash length, thickness, pigmentation, and number of lashes. The mechanism of change in lash structure and the long-term effects of this action are currently unknown.

There is no experience with travoprost in inflammatory eye disease, neovascular glaucoma, closed angle glaucoma, narrow angle glaucoma or congenital glaucoma, and only limited experience with eye disease caused by thyroid disorders, in glaucoma in patients with pseudophakia. in pigmentary or pseudoexfoliative glaucoma.

The drug is recommended with caution in patients with aphakia, pseudophakia, posterior lens capsule rupture, with risk factors for cystoid macular edema.

Contact of travoprost with the skin should be avoided because studies in rabbits have shown transdermal absorption of travoprost.

Patients with risk factors for iritis/veitis should be cautiously prescribed.

Patients should remove contact lenses before injecting the drug. Wait 15 minutes after insertion before reinserting contact lenses.

Transient blurred vision or other visual disturbances after use of the drug may affect the ability to operate vehicles and machinery. If blurred vision occurs after injecting the drug, the patient must wait until visual clarity is restored before driving motor vehicles and operating machinery.

Contraindications

Hypersensitivity to the components of the drug, children under 18 years of age, pregnancy and breast-feeding.

The drug should be used with caution in patients with aphakia; in patients with pseudophakia when the posterior lens capsule has ruptured or in patients with an anterior chamber intraocular lens; in patients at risk of cystoid macular edema.

The drug should be used with caution in patients with acute inflammation of the visual organ and in patients with risk factors predisposing to iritis, uveitis.

Side effects

The overall profile of adverse reactions according to clinical studies showed that conjunctival injection and iris hyperpigmentation were the most common adverse events, with an incidence of 20 and 6%, respectively.

The adverse reactions detected during post-registration use of the drug were classified as follows: Very common (≥1/10); common (≥1/100 and < 1/10); infrequent (≥1/1000 and < 1/100); rare (≥1/10000 and < 1/1000); very rare (< 1/10000) and frequency unknown (cannot be estimated from available data). In each group, adverse events are presented in decreasing order of severity. Adverse events are reported in clinical trials and post-registration follow-up.

Adverse Event Profile in Pediatric Practice

In a 3-month phase 3 study and a 7-day pharmacokinetic study involving 102 pediatric patients, the adverse event profile was consistent with that of adult patients. Short-term safety profiles in different subpopulations of the pediatric population were also similar.

The most common adverse reactions in the pediatric population were conjunctival injection (16.9%) and increased eyelash growth (6.5%). In a similar 3-month study in adult patients, these adverse events occurred at rates of 11.4% and 0.0%, respectively. Additionally, in the pediatric population (n=77), a 3-month clinical trial similar to the one in adults (n=185) reported single cases of eyelid erythema, keratitis, lacrimation, and photophobia with an overall adverse event rate of 1.3% compared to 0.0% in the adult population.

Overdose

Pregnancy use

Similarities